NCT07090499 2026-03-19A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsPfizerPhase 1 Recruiting310 enrolled
NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT04682431 2024-03-22A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated127 enrolled
NCT04452214 2023-07-14A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCantargia ABPhase 1 Completed19 enrolled
NCT00101972 2022-02-22RAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaMacroGenicsPhase 1 Completed53 enrolled
NCT01976741 2021-05-06Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)BayerPhase 1 Completed168 enrolled 59 charts